Epic Sciences, Station X Link Up to Analyze CTC Data for CDx Development

Print 25 January 2016
GenomeWeb

NEW YORK (GenomeWeb) – Epic Sciences has announced it will use Station X's GenePool platform as part of data analysis for its collaborations with pharmaceutical companies to develop circulating tumor cell-based companion diagnostics.

GenePool is a web-based software service that allows researchers to analyze and share data. The software is pre-loaded with standard clinical reporting capabilities for incidental findings and tumor profiling, but is also customizable, Station X said in a statement.

"Station X delivers a sophisticated data management and collaboration platform that is allowing us to deliver on our strategy to develop a robust commercial platform with a strong and diverse pipeline of diagnostic and companion diagnostic products," Mark Landers, Director of Genomics at Epic Sciences, said in a statement. The firm noted it is developing companion diagnostics in partnership with pharmaceutical companies in more than 50 active clinical trials.

The deal comes as San Francisco-based Station X begins to align itself with firms offering liquid biopsy technology and services. Last month, the firm announced a partnership with Circulogene.

For Epic Sciences, the announcement comes on the heels of a partnership with the University of Pennsylvania to find biomarkers using CTC technology, announced in November 2015, and CAP accreditation for its San Diego laboratory earlier this month.

Source

Return